Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Seeking Alpha
The development follows the release of positive phase 1 data on the candidate on Dec. 8 that sent shares surging KT-621 is currently in phase 2. More on Kymera Therapeutics Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis - Slideshow Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum Kymera Therapeutics prices $602M public offering at $86.00 a share Kymera Therapeutics announces $500M proposed public offering Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.MarketBeat
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.MarketBeat
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic DermatitisGlobeNewswire
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 12/12/25 - Form 4
- 12/12/25 - Form 144
- 12/12/25 - Form 144
- KYMR's page on the SEC website